Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an update.
On May 12, 2025, Biodexa Pharmaceuticals announced that the European Commission granted Orphan Drug Designation for their product eRapa, aimed at treating familial adenomatous polyposis (FAP), a precancerous colon disease. This designation, which follows a similar one from the FDA in 2019, positions Biodexa to begin a registrational Phase 3 study, supported by significant funding, targeting a $7.3 billion addressable market. The designation provides 10 years of marketing exclusivity and special regulatory incentives, potentially enhancing Biodexa’s market position and offering significant benefits to stakeholders.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs. Their lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers. The company utilizes proprietary drug delivery technologies to enhance bio-delivery and bio-distribution of medicines, with headquarters in Cardiff, UK.
Average Trading Volume: 1,576,554
Technical Sentiment Signal: Sell
Current Market Cap: $942.7K
Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.